Antioxidant response in patients with chronic hepatitis B or C.



Similar documents
Co-infected health-care workers

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

2015 Outpatient Chronic Hepatitis B Management

Viral Hepatitis APHL survey report

Viral Hepatitis Case Report

HBsAg level and hepatitis B viral load correlation with focus on pregnancy

Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B

Commonly Asked Questions About Chronic Hepatitis C

HBV DNA < monitoring interferon Rx

EVALUATION OF LIVER FIBROSIS BY FIBROSCAN

Management of Chronic Hepatitis B: 2012 Update

Patterns of abnormal LFTs and their differential diagnosis

THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

National Health Burden of CLD in Italy

The Physiology of Hyperbaric Oxygen Therapy. Free Radicals and Reactive Oxygen Species. I. Introduction Definition, Source, function and Purpose

SHAHID AZIZ DO, FACOI.

Hepatitis C. David Mutimer Queen Elizabeth Hospital Liver Unit Birmingham. Substance Misuse Treatment in the West Midlands. How can we reduce harm?

The Natural History of Chronic Hepatitis B Virus Infection

PURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.

Case Finding for Hepatitis B and Hepatitis C

NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center

Optimising therapy in chronic hepatitis B: Switch or add treatment

Cirrhosis and HCV. Jonathan Israel M.D.

HBV Treatment Guidelines. By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine

CASL Symposium Hepatitis B Co-chairs: Carla Coffin and Mang Ma

Conveners: S. Bruno, C.M. Mastroianni

Clinical Criteria for Hepatitis C (HCV) Therapy

Study of Thrombocytopenia in Chronic Hepatitis C

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

Treatment Strategies of Hepatitis B in China

Boehringer Ingelheim- sponsored Satellite Symposium. HCV Beyond the Liver

Approach to Abnormal Liver Tests

21.8 The Citric Acid Cycle

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

1.1.2 Amend the that the Special Authority relating to tenofovir for use in pregnancy for postpartum care;

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

Tema 6. Curcuminoides. Estructura Similitud con otras biomoléculas naturales Biodisponibilidad Efectos moleculares Metabolismo

Hepatitis C. Laboratory Tests and Hepatitis C

Transmission of HCV in the United States (CDC estimate)

Dosaggi Sierologici e Molecolari nelle Epatiti B e C METODI MOLECOLARI. Ombretta Turriziani Dipartimento di Medicina Molecolare

What to Do with the Patient With Abnormal Liver Enzymes? Nizar N. Zein, M.D. The Cleveland Clinic

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

Review: How to work up your patient with Hepatitis C

Antioxidant Products. A comprehensive range of. Antioxidants

Albumin. Prothrombin time. Total protein

Non-alcoholic fatty liver disease: Prognosis and Treatment

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

OZONE THERAPY IN PATIENTS WITH VIRAL HEPATITIS C A CLINICAL STUDY

Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014

HCV: Diagnostic Testing and Staging. HCV: Diagnostic Tests

Treatment of Hepatitis B

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide

HEPATITIS C. The Facts. Get Tested. Get Cured! Health

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs

BURDEN OF LIVER DISEASE IN BRAZIL

Fat and Viral Liver Disease

Hepatitis C Glossary of Terms

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok

Medical publications on HBV and HCV Coinfection

Pharmacogenetic Activities in SWOG Breast Cancer

Clinical Criteria for Hepatitis C (HCV) Therapy

EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B September, 2002 Geneva, Switzerland Consensus statement (Short version)

Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

HEPATITIS COINFECTIONS

1.How did I get Hepatitis C?

The availability of newer antiviral agents, as

Liver Disease and Therapy of Hepatitis B Virus Infections

HBV screening and management in HIV-infected children and adolescents

2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line

Is Exercise the Best Antioxidant Supplement? Len Kravitz, Ph.D.

BIOMARKERS AND TOXICITY MECHANISMS 06 Mechanisms Metabolism & Detoxification. Luděk Bláha, PřF MU, RECETOX

New IDSA/AASLD Guidelines for Hepatitis C

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

An Investigation of Alcohol Metabolizing Enzyme Genes in Chinese Alcoholics With Pancreatitis,, Cirrhosis of Liver, and Avascular Necrosis of Hip

CELLULE STELLATE EPATICHE E DANNO METABOLICO. Fabio Marra Dipartimento di Medicina Interna Centro di Eccellenza DenoTHE Università di Firenze

The Epidemiology of Hepatitis A, B, and C

Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 study.

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

Virology. Behandlung der Hepatitis B. HBV Genome. HBV life cycle. HBV Genotypes. Natural History. 8 genotypes: A, B, C, D, E, F, G, H

HBV Quantitative Real Time PCR Kit

HIV and Hepatitis B CoInfection

Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C)

Results Demographic profile of these children is shown in Table I.

Mutations: 2 general ways to alter DNA. Mutations. What is a mutation? Mutations are rare. Changes in a single DNA base. Change a single DNA base

Summary and conclusion 2013

Appendix B: Provincial Case Definitions for Reportable Diseases

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Hepatitis C Agents

Publikationsliste Claudia Götz

Comparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases

Update on Hepatitis C. Sally Williams MD

Chronic hepatitis B (CHB) remains an important public SPECIAL REPORT

Performance of a New-Generation Chemiluminescent Assay for Hepatitis B Surface Antigen

Ribavirin/Pegylated Interferon Combination Therapy for People with Hepatitis C

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

THE MORINGA ANTIOXIDANT ASSORTMENT, TELOMERES AND AGING. Dr. Howard W. Fisher

Focus on Transplantation: Treatment Post-transplant for HBV and HCV

Transcription:

Antioxidant response in patients with chronic hepatitis B or C. Kamila Wójcik, Anna Piekarska, Elżbieta Jabłonowska Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland

Oxidative stress HCV core proteins and HBV X protein increase the mitochondrial production of reactive oxygen species (ROS),which induces oxidative stress and results in the peroxidation of membrane lipids and cell death. Okuda M. Gastroenterology 2002 Waris G. Mol Cell Biol 2001

Oxidative stress in HCV infection Reactive oxygen species (ROS) production can suppress HCV replication. Choi J. Hepatology 2004 Excessive production of ROS may cause hepatocyte damage. Mutlu-Turkoglu U. Res Commun Mol Pathol Pharmacol 1997 Antioxidant enzymes, such as Heme oxygenase-1 (HO- 1), induced in response to stressful stimuli, play a crucial role by suppressing inflammation and protecting against oxidative stress. Abraham NG. Pharmacol Rev 2008

Antioxidant response Upon oxidative stress, an adaptive antioxidant response is harnessed by the liver to sustain redox homeostasis and cellular integrity. Central to this self-protective antioxidant mechanism is the Nuclear factor (erythroidderived 2)-like 2 (Nrf2), encoded by the NFE2L2 gene. Nguyen T. Annu Rev Pharmacol Toxicol 2003

Antioxidant response

Antioxidant response Nrf2 binds to a conserved antioxidant response element (ARE) and is responsible for the transcriptional activation of cytoprotective genes. Bach1 (BTB and CNC homology 1, basic leucine zipper transcription factor 1) is a transcriptional repressor that antagonizes NRF2 binding to an antioxidant response element. Jyrkkänen HK. Biochem J 2011

Aims of study To analyze the antioxidant response and its regulatory factors in chronic hepatitis B and C.

Aims To examine the expression of the antioxidant genes GFER1(Growth factor erv1-like), HMOX-1 (heme oxygenase (decycling)-1) and NQO-1 (NAD(P)H:quinone oxidoreductase-1) in liver biopsy specimens obtained from patients with chronic hepatitis B or C. To investigate the importance of the regulatory genes NFE2L2 (nuclear factor erythroid 2-related factor 2) and Bach1 (BTB and CNC homology 1, basic leucine zipper transcription factor 1) in the antioxidant response.

Inclusion criteria Chronic hepatitis B (diagnosed as the presence of HBsAg, anti-hbeag and HBV-DNA (PCR) positivity and anti-hbe negativity for longer than 6 months). Chronic hepatitis C genotype 1 (based on anti- HCV and HCV-RNA (PCR) positivity lasting more than 6 months). All patients provided their written informed consent and the study was approved by the local Bioethics Committee.

Exclusion criteria cirrhosis (in liver biopsy), other causes of liver diseases, other systemic or inflammatory diseases, alcoholism, pregnancy, use of concomitant medication, including antioxidant vitamin and diet supplements within 6 months

Methods Liver biopsy was performed in all patients prior to treatment. The grade of inflammation and necrotic changes and the state of fibrosis were assessed according to the Batts and Ludwig scale. The hepatic expression of HMOX-1, GFER1, NQO-1,NFE2L2 and Bach-1 were determined using Real-Time PCR (RT-PCR).

Statistical analysis The Mann-Whitney test was used to evaluate differences between the examined groups. Correlations between hepatic expression of antioxidant genes HMOX-1, GFER1, NQO-1 and regulatory gene NFL2L2 and Bach-1 were analyzed with the Spearman rank correlation coefficient.

Results The study group consisted of 76 patients (42 with chronic HCV and 34 with chronic HBV infection).

Characteristics of the study group HCV infection (n=42) HBV infection (n=34) p MEDIAN LQ-UQ MEDIAN LQ-UQ Age in years 32 21-49 29.5 23-41 >0.5 ALT U/l 54 39-83 37 25-54 >0.5 HCV-RNA IU/ml 4 145 000 388 000-6 890 000 HBV-DNA copies/ml 54 007 15 464-333 899 Number of patients Fraction Number of patients Fraction G<2 30 71.42 29 85.29 >0.5 G 2 12 28,58 5 14.71 S<2 8 19,1 13 38.23 >0.5 S 2 34 80,9 21 61.77 Age >40 years 14 33.33 8 23.53 >0.5 Age <40 years 28 66.67 26 76.47 Women 11 26.19 9 26.47 >0.5 Men 31 73.81 25 73.53

Hepatic expression of antioxidant genes HMOX1, GFER1, NQO-1 in chronic hepatitis B or C HCV infection HBV infection MEDIAN LQ-UQ MEDIAN LQ-UQ p HMOX-1 10.05 4.05-20.72 34.53 21.21-79.50 <0.0001 GFER 1 1.46 0.98-2.05 2.49 1.74-3.64 0.0008 NQO-1 1.46 0.98-1.69 1.51 0.42-2.80 0.16 BACH1 3.73 1.76-9.45 2.52 1.64-4.71 0.15 NFE2L2 2.30 1.50-3.83 3.68 2.10-6.63 0.009

Correlations between hepatic expression of antioxidant genes and the regulatory gene NFE2L2 in chronic hepatitis B or C HCV infection HBV infection Spearman`s rank correlation p-value Spearman`s rank correlation p-value GFER 1vs NFE2L2 HMOX-1 vs NFE2L2 NQO-1 vs NFE2L2 0.22 0.16 0.68 <0.0001 0.65 0.001 0.69 <0.0001 0.59 <0.0001 0.79 <0.0001

Conclusions The hepatic expression of the antioxidant genes HMOX-1, GFER 1 and NQO-1 is higher in patients with chronic HBV than those with chronic HCV infection, and may be associated with better antioxidant response in the course of HBV infection. Dysregulation of NFE2L2 and Bach1 in patients with chronic hepatitis C is involved in impaired antioxidant response.